Impact of melphalan dose during reduced-intensity conditioning on engraftment of cord blood transplantation for chronic Epstein-Barr virus-associated T or NK cell lymphoproliferative diseases.
Adolescent
Adult
Antilymphocyte Serum
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Child
Child, Preschool
Combined Modality Therapy
Cord Blood Stem Cell Transplantation
/ adverse effects
Epstein-Barr Virus Infections
/ complications
Etoposide
/ administration & dosage
Female
Follow-Up Studies
Graft vs Host Disease
/ etiology
Herpesvirus 4, Human
/ isolation & purification
Humans
Infant
Infant, Newborn
Killer Cells, Natural
/ immunology
Lymphoproliferative Disorders
/ immunology
Male
Melphalan
/ administration & dosage
Prognosis
Retrospective Studies
Survival Rate
T-Lymphocytes
/ immunology
Transplantation Conditioning
Transplantation, Homologous
Vidarabine
/ administration & dosage
Young Adult
chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases
chronic active Epstein-Barr virus infection
cord blood transplantation
engraftment
reduced-intensity conditioning
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
24
11
2019
revised:
26
05
2020
accepted:
09
06
2020
pubmed:
22
6
2020
medline:
15
12
2020
entrez:
22
6
2020
Statut:
ppublish
Résumé
The rejection rate in cord blood transplants for chronic Epstein-Bar virus-associated T or natural killer cell lymphoproliferative diseases using our standard reduced-intensity conditioning "LPAM140 regimen," which includes fludarabine, melphalan (LPAM), etoposide, and antithymocyte globulin, has been high. To ensure better engraftment, we increased the LPAM dose to 210 mg/m
Substances chimiques
Antilymphocyte Serum
0
Etoposide
6PLQ3CP4P3
Vidarabine
FA2DM6879K
fludarabine
P2K93U8740
Melphalan
Q41OR9510P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28536Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kawa K. Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease. Int J Hematol. 2003;78:24-31.
Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673-686.
Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease. Blood. 2011;117:5835-5849.
Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.
Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease. Blood. 2018;131:2899-2905.
Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46:77-83.
Sawada A, Inoue M, Koyama-Sato M, et al. Umbilical cord blood as an alternative source of reduced-intensity hematopoietic stem cell transplantation for chronic Epstein-Barr virus-associated T or natural killer cell lymphoproliferative diseases. Biol Bone Marrow Transplant. 2014;20:214-221.
Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105:406-418.